Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.0%

2 terminated/withdrawn out of 200 trials

Success Rate

96.2%

+9.7% vs industry average

Late-Stage Pipeline

13%

25 trials in Phase 3/4

Results Transparency

6%

3 of 50 completed trials have results

Key Signals

34 recruiting3 with results

Enrollment Performance

Analytics

N/A
67(49.6%)
Phase 2
38(28.1%)
Phase 3
13(9.6%)
Phase 4
12(8.9%)
Phase 1
3(2.2%)
Early Phase 1
2(1.5%)
135Total
N/A(67)
Phase 2(38)
Phase 3(13)
Phase 4(12)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (200)

Showing 20 of 200 trials
NCT07533695Not ApplicableNot Yet Recruiting

Impact of Day 2 Versus Day 3 Fresh Embryo Transfer on Live Birth Rate in Poor-Prognosis Patients

Role: lead

NCT04849104Active Not Recruiting

Cohort Study of Airway Microecology and the Pathogenesis and Evolution of Chronic Obstructive Pulmonary Disease

Role: lead

NCT07505251Not Yet Recruiting

Development and Validation of the Periodontal Map Derived From IOS and CBCT Registration for Diagnosis and Treatment Planning in Moderate-to-severe Periodontitis

Role: lead

NCT07490561Not ApplicableNot Yet Recruiting

The Impact of Assisted Hatching on Pregnancy Outcomes After Vitrified-Warmed Embryo Transfer in Advanced-age Patients

Role: lead

NCT07466810Not ApplicableNot Yet Recruiting

Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology

Role: lead

NCT07029178Phase 2Recruiting

Taurine's Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis

Role: lead

NCT07474493Not ApplicableRecruiting

Comparing Cleaning Tools for Full-Arch Implant-Supported Fixed Prostheses

Role: lead

NCT07470996Recruiting

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR

Role: collaborator

NCT07353463Recruiting

Shanghai Clinical Cohort - Parkinson's Disease (Reserve)

Role: collaborator

NCT07445048Phase 3Not Yet Recruiting

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Bemcentinib in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

Role: lead

NCT07414758Phase 3Recruiting

Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy

Role: collaborator

NCT07415265Completed

Bone Barrier Technique for Compromised Immediate Implants

Role: lead

NCT07406867Not Yet Recruiting

Diagnostic Accuracy of Oral Images, OPGs, Biomarkers and Questionnaires vs. Clinical Assessment for Periodontal Disease (PostNCT07164573)

Role: lead

NCT06190275Not ApplicableRecruiting

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

Role: collaborator

NCT07353073Phase 2Not Yet Recruiting

A Prospective, Single-Arm, Phase II Clinical Study of Neoadjuvant Therapy With Pucotenlimab, Lenvatinib, and Temozolomide for Resectable Head and Neck Mucosal Melanoma (PLT-NAT-HNMM-II)

Role: lead

NCT07349095Not ApplicableRecruiting

AI-Assisted Colorimetric Diagnosis of Peri-Implant Mucosal Erythema

Role: lead

NCT07320690Phase 3Not Yet Recruiting

De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Role: lead

NCT07293481Recruiting

Discovery and Validation of Periodontitis Biomarkers

Role: lead

NCT05171842Completed

Dissection of the Superior Mesenteric Artery

Role: collaborator

NCT07190820Not ApplicableNot Yet Recruiting

Comparison of Accuracy of Full-arch Implant Digital and Conventional Impressions.

Role: lead